Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Eplerenone (Primary) ; Spironolactone
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 May 2018.
- 10 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.
- 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.